Divya Ayyala-Somayajula, MD, MS

Assistant Professor of Medicine
Director, Alcohol-Associated Liver Disease Program

Contact Information

Divya Ayyala-Somayajula, MD, MS

132 S. 10th Street
Suite 480, Main Building
Philadelphia , PA 19107

Email Divya Ayyala-Somayajula

215-955-8900
215-503-2146 fax

Assistant Professor of Medicine
Director, Alcohol-Associated Liver Disease Program

Education

Medical School

University of Southern California Keck School of Medicine, MD - 2017

Residency 

Internal Medicine,Los Angeles General Hospital; University of Southern California, Los Angeles, CA - 2020

Fellowships

Gastroenterology, Los Angeles General Hospital+ University of Southern California, Los Angeles, CA - 2023
Transplant Hepatology,  University of Southern California, Los Angeles, CA - 2024

Additional Training

MS in Clinical, Biomedical, & Translational Investigations 

Publications

Awards

  • 2024 AASLD Healthcare Disparities Research Award
  • 2023 AASLD Transplant Hepatology Fellow Award
  • 2023 USC GI Fellow of the Year
  • 2023 Young Investigators Forum Best Abstract Presentation “Controversies of Liver Transplantation”
  • 2022 GUILD Fellows Program Participant 

Memberships

  • American Association of the Study of Liver Disease, Member, 2020-Present
  • American Society of Transplantation, Member 2023-Present
  • Women’s Initiative Committee, American Association of the Study of Liver Disease (member, 2024)
  • Alcohol Associated Liver Disease Special Interest Group, Member at Large steering committee (member, 2025-)

Research & Clinical Interests

As the director of the alcohol-associated liver disease (ALD) program at Thomas Jefferson University, I have a strong clinical interest in treating patients with ALD and alcohol use disorder and have been engaged in clinical patient-oriented research throughout my career.

My primary research interests include identifying barriers to care and potential cost-effective interventions in the alcohol-associated liver disease population. I completed a Masters in Clinical, Biomedical, and Translational Investigation which led to several research projects describing the epidemiology of alcohol related illness and the interplay between alcohol, liver disease, and financial toxicity published in peer reviewed journals. I have participated in clinical trials involving novel interventions for alcohol associated hepatitis and conducted a prospective pilot study evaluating the feasibility and safety of acamprosate in post-liver transplant patients with a history of alcohol associated liver disease.